Glutodine | CAS# 58131-49-0 | antihistamine

MedKoo Cat#: 575911 | Name: Cyproheptadine 2-Ketoglutarate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cyproheptadine, Glutodine, is a first-generation antihistamine with additional antiserotonergic, anticholinergic and local anesthetic properties. Glutodine is a white to slightly yellowish crystalline solid, which is soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform, and practically insoluble in ether.

Chemical Structure

Cyproheptadine 2-Ketoglutarate

CAS#58131-49-0 (2-Ketoglutarate)

Theoretical Analysis

MedKoo Cat#: 575911

Name: Cyproheptadine 2-Ketoglutarate

CAS#: 58131-49-0 (2-Ketoglutarate)

Chemical Formula: C26H27NO5

Exact Mass: 433.1889

Molecular Weight: 433.50

Elemental Analysis: C, 72.04; H, 6.28; N, 3.23; O, 18.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

129-03-3 (free base) 58131-49-0 (2-Ketoglutarate) 41354-29-4 (HCl hydrate)

Synonym

Cyproheptadine; Glutodine;

IUPAC/Chemical Name

Piperidine, 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-methyl-, 2-oxopentanedioate (1:1)

InChi Key

LFIWQECRMKMNIM-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H21N.C5H6O5/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21;6-3(5(9)10)1-2-4(7)8/h2-11H,12-15H2,1H3;1-2H2,(H,7,8)(H,9,10)

SMILES Code

CN1CCC(=C2c3ccccc3C=Cc4ccccc24)CC1.OC(=O)CCC(=O)C(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Cyproheptadine is used to treat allergic reactions (specifically hay fever), Vasomotor rhinitis, Allergic conjunctivitis due to inhalant allergens and foods, uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma, Cold urticaria, and Dermatographism. Cyproheptadine is used off-label to treat Spasticity Associated With Spinal Cord, Migraine Headache Prophylaxis, Decreased Appetite Secondary to Chronic Disease, Drug-Induced Sexual Dysfunction, Serotonin Syndrome.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 433.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tkach N, Opler DJ. A Consideration for the Study of the Use of Cyproheptadine in Parkinson Disease Psychosis. J Clin Psychopharmacol. 2023 Sep-Oct 01;43(5):481-482. doi: 10.1097/JCP.0000000000001743. Epub 2023 Aug 4. PMID: 37683250. 2: Boniatti MM, Nedel WL, Rihl MF, Schwarz P, Parolo E, Moretti MMS, Lisboa TC. Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial. Indian J Crit Care Med. 2023 Jul;27(7):517-521. doi: 10.5005/jp-journals-10071-24482. PMID: 37502298; PMCID: PMC10369312. 3: Nagy A, Nasir A, Haque M, Judge R, Lee J. Therapeutic cyproheptadine regimen in serotonin syndrome: Complications after cardiovascular surgery. Clin Case Rep. 2023 Jul 18;11(7):e7720. doi: 10.1002/ccr3.7720. PMID: 37476598; PMCID: PMC10354353. 4: Gupta M, Gupta N, Madabushi J. Off-Label Cyproheptadine in Children and Adolescents: Psychiatric Comorbidities, Interacting Variables, Safety, and Risks of Hepatotoxicity. Cureus. 2023 Jan 13;15(1):e33745. doi: 10.7759/cureus.33745. PMID: 36788882; PMCID: PMC9922522. 5: Cui H, Yang J, Yang B, Hao Y, Shi X, Zhang D, Yang X, Zhang T, Zhao D, Yuan X, Chen X, Liu X, Zheng H, Zhang K. Cyproheptadine hydrochloride inhibits African swine fever viral replication in vitro. Microb Pathog. 2023 Feb;175:105957. doi: 10.1016/j.micpath.2022.105957. Epub 2022 Dec 23. PMID: 36572196. 6: Kamper D, Barry A, Bansal N, Stoykov ME, Triandafilou K, Vidakovic L, Seo N, Roth E. Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke. J Stroke Cerebrovasc Dis. 2022 Oct;31(10):106724. doi: 10.1016/j.jstrokecerebrovasdis.2022.106724. Epub 2022 Aug 30. PMID: 36054974; PMCID: PMC9533231. 7: Sankrityayan H, Kale A, Shelke V, Gaikwad AB. Cyproheptadine, a SET7/9 inhibitor, reduces hyperglycaemia-induced ER stress alleviating inflammation and fibrosis in renal tubular epithelial cells. Arch Physiol Biochem. 2022 Aug 1:1-9. doi: 10.1080/13813455.2022.2105365. Epub ahead of print. PMID: 35913792. 8: Marsit O, Clavel MA, Paquin A, Deschênes V, Hadjadj S, Sénéchal-Dumais I, Couet J, Arsenault M, Handschumacher MD, Levine RA, Aikawa E, Pibarot P, Beaudoin J. Effects of Cyproheptadine on Mitral Valve Remodeling and Regurgitation After Myocardial Infarction. J Am Coll Cardiol. 2022 Aug 2;80(5):500-510. doi: 10.1016/j.jacc.2022.05.025. PMID: 35902173. 9: Petroianu GA. Hyperthermia and Serotonin: The Quest for a "Better Cyproheptadine". Int J Mol Sci. 2022 Mar 20;23(6):3365. doi: 10.3390/ijms23063365. PMID: 35328784; PMCID: PMC8952796. 10: Feng YM, Chen TH, Berman D, Chou CK, Liao KS, Hsieh MC, Chen CY. Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report. Front Oncol. 2021 Oct 20;11:620212. doi: 10.3389/fonc.2021.620212. PMID: 34745929; PMCID: PMC8563693. 11: Bertrand V, Massy N, Vegas N, Gras V, Chalouhi C, Tavolacci MP, Abadie V. Safety of Cyproheptadine, an Orexigenic Drug. Analysis of the French National Pharmacovigilance Data-Base and Systematic Review. Front Pediatr. 2021 Sep 29;9:712413. doi: 10.3389/fped.2021.712413. PMID: 34676184; PMCID: PMC8525494. 12: Lin YC, Yen HR, Tsai FJ, Wang CH, Chien LC, Chen AC, Lin RT. Effects of cyproheptadine on body weight gain in children with nonorganic failure to thrive in Taiwan: A hospital-based retrospective study. PLoS One. 2021 Oct 19;16(10):e0258731. doi: 10.1371/journal.pone.0258731. PMID: 34665812; PMCID: PMC8525746. 13: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Cyproheptadine. 2021 Sep 20. PMID: 30000753. 14: Kim SY, Yun JM, Lee JW, Cho YG, Cho KH, Park YG, Cho B. Efficacy and Tolerability of Cyproheptadine in Poor Appetite: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. Clin Ther. 2021 Oct;43(10):1757-1772. doi: 10.1016/j.clinthera.2021.08.001. Epub 2021 Sep 8. PMID: 34509304. 15: Jou YC, Lin GL, Lin HY, Huang WH, Chuang YM, Lin RI, Chen PC, Wu SF, Shen CH, Chan MWY. Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma. Cancer Cell Int. 2021 Apr 19;21(1):226. doi: 10.1186/s12935-021-01925-9. PMID: 33874979; PMCID: PMC8054409. 16: Grunert J, van der Haak N, La Vanda C, Farrow N, Tai A. Cyproheptadine as an appetite stimulant in children with cystic fibrosis. Clin Nutr ESPEN. 2021 Apr;42:407-409. doi: 10.1016/j.clnesp.2021.01.015. Epub 2021 Feb 5. PMID: 33745614. 17: Kacar S, Hacioglu C, Kar F, Sahinturk V, Kanbak G. Cyproheptadine causes apoptosis and decreases inflammation by disrupting thiol/disulfide balance and enhancing the levels of SIRT1 in C6 glioblastoma cells. Toxicol In Vitro. 2021 Jun;73:105135. doi: 10.1016/j.tiv.2021.105135. Epub 2021 Mar 4. PMID: 33675893. 18: Badr B, Naguy A. Cyproheptadine: a psychopharmacological treasure trove? CNS Spectr. 2022 Oct;27(5):533-535. doi: 10.1017/S1092852921000250. Epub 2021 Feb 26. PMID: 33632345. 19: Murray BP, Carpenter JE, Sayers J, Yeh M, Beau J, Kiernan EA, Wolf MJ, Bolton TA, Kazzi Z. Two Cases of Serotonin Syndrome After Bupropion Overdose Treated With Cyproheptadine. J Emerg Med. 2021 Apr;60(4):e67-e71. doi: 10.1016/j.jemermed.2020.10.039. Epub 2020 Dec 8. PMID: 33308914. 20: Abdelrahman MM, Abdelaleem EA, Ali NW, Emam RA. Development and Validation of Stability Indicating High-Performance Liquid Chromatographic Method for Determination of Cyproheptadine Hydrochloride, its Impurity And Degradation Product. J Chromatogr Sci. 2021 Jan 14;59(2):128-133. doi: 10.1093/chromsci/bmaa085. PMID: 33137815.